Read more

October 31, 2024
1 min watch
Save

VIDEO: Vevye ‘changing the landscape’ in treatment of dry eye

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Ranjan P. Malhotra, MD, FACS, discusses how Vevye, a higher-concentration formulation of cyclosporine, is “changing the landscape” in dry eye.

Vevye (cyclosporine ophthalmic solution 0.1%, Harrow) addresses the tolerability issue faced by patients with dry eye, as it offers a nonburning, nonstinging therapy that works quickly to treat the signs and symptoms of dry eye within 2 weeks, according to Malhotra, of Ophthalmology Associates in the St. Louis area.

“It’s created a big splash, even though cyclosporine has been around for over 20 years,” he said. “This formulation of cyclosporine is not only a higher concentration, the vehicle makes it more bioavailable, and it translates clinically.”